导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.20% | 1665/4763 |
| 近一周 | -1.52% | 2256/5452 |
| 近一月 | -2.31% | 1572/5409 |
| 近一季 | -4.24% | 1765/5219 |
| 近半年 | 0.90% | 1234/4908 |
| 近一年 | 5.80% | 1657/4388 |
| 近两年 | 44.68% | 1683/2951 |
| 近三年 | 30.69% | 1065/2250 |
| 成立以来 | 186.27% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.05% 2652/4961 |
12.50% 2168/5312 |
- - |
- - |
| 2025 | 16.49% 2450/4813 |
-0.34% 2211/3635 |
1.42% 2337/4076 |
14.93% 2858/4524 |
0.28% 2084/4813 |
| 2024 | 16.02% 852/3463 |
4.42% 456/2808 |
-1.03% 900/3014 |
15.19% 1791/3129 |
-2.54% 2122/3463 |
| 2023 | -7.99% 972/2656 |
5.10% 830/2280 |
-4.12% 1062/2385 |
-3.06% 839/2515 |
-5.81% 1512/2655 |
| 2022 | -19.08% 799/2207 |
-13.03% 687/1919 |
5.60% 861/2016 |
-13.04% 823/2113 |
1.33% 1301/2208 |
| 2021 | 1.41% 676/1822 |
-2.09% 581/1255 |
6.67% 729/1330 |
-3.73% 658/1466 |
0.86% 1051/1822 |
| 2020 | 38.83% 347/1250 |
-7.24% 532/1028 |
16.02% 462/1067 |
17.78% 97/1164 |
9.52% 636/1184 |
| 2019 | 36.23% 361/1092 |
21.97% 584/754 |
0.53% 168/804 |
2.84% 282/850 |
8.03% 362/918 |
| 2018 | -21.97% 227/834 |
- - |
- - |
- - |
-12.11% 402/691 |
| 2017 | 25.90% 108/714 |
- - |
- - |
- - |
- - |
| 2016 | -7.99% 236/605 |
- - |
- - |
- - |
- - |
| 2015 | 22.06% 106/575 |
- - |
- - |
- - |
- - |
| 2014 | 23.80% 186/237 |
- - |
- - |
- - |
- - |
| 2013 | 13.01% 36/186 |
- - |
- - |
- - |
- - |
| 2012 | 11.20% 36/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 建信沪深300指数增强(LOF)A VS. 长安沪深300非周期A(740101) |